Vericel (VCEL) Stock Forecast, Price & News

Vericel (NASDAQ:VCEL) Frequently Asked Questions

Is Vericel a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vericel stock.
View analyst ratings for Vericel or view top-rated stocks.

When is Vericel's next earnings date?

Vericel is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Vericel.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) posted its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.03. The biotechnology company earned $36.07 million during the quarter, compared to analyst estimates of $34.31 million. Vericel had a negative trailing twelve-month return on equity of 6.93% and a negative net margin of 7.15%. The firm's revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.07) earnings per share.
View Vericel's earnings history.

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $178.00 million-$189.00 million, compared to the consensus revenue estimate of $183.55 million.

What price target have analysts set for VCEL?

3 brokerages have issued 12 month price objectives for Vericel's shares. Their forecasts range from $45.00 to $52.00. On average, they expect Vericel's stock price to reach $48.50 in the next year. This suggests a possible upside of 80.7% from the stock's current price.
View analysts' price targets for Vericel or view top-rated stocks among Wall Street analysts.

Who are Vericel's key executives?

Vericel's management team includes the following people:

• Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 58, Pay $1.36M)
• Mr. Joseph Anthony Mara Jr., CFO & Treasurer (Age 46, Pay $636.24k)
• Mr. Michael Halpin, Chief Operating Officer (Age 61, Pay $672.86k) (LinkedIn Profile)
• Mr. Sean C. Flynn, Sr. VP, Gen. Counsel & Sec. (Age 48, Pay $556.66k) (LinkedIn Profile)
• Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B., Chief Medical Officer (Age 60, Pay $578.36k)
• Mr. Jonathan Siegal, Principal Accounting Officer, VP & Corp. Controller
• Mr. Eric Burns, Exec. Director of Financial Planning and Analysis & Investor Relations
• Mr. Patrick J. Fowler, Sr. VP of Corp. Devel. & Strategy
• Ms. Heidi Hassen, VP of HR
• Mr. Roland DeAngelis, Sr. VP of Commercial Operations

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel CEO Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among Vericel's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Vericel's key competitors?

Some companies that are related to Vericel include Ginkgo Bioworks (DNA), CRISPR Therapeutics (CRSP), Novavax (NVAX), Ablynx (ABLYF), Abcam (ABCM), Vir Biotechnology (VIR), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Beam Therapeutics (BEAM), Bavarian Nordic A/S (BVNRY), Fate Therapeutics (FATE), Twist Bioscience (TWST), SpringWorks Therapeutics (SWTX), Relay Therapeutics (RLAY) and BioCryst Pharmaceuticals (BCRX).
View all of VCEL's competitors.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.08%), RTW Investments LP (8.53%), Vanguard Group Inc. (6.38%), State Street Corp (6.24%), Conestoga Capital Advisors LLC (5.53%) and Federated Hermes Inc. (3.45%). Company insiders that own Vericel stock include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends for Vericel.

Which major investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Federated Hermes Inc., Invesco Ltd., UBS Group AG, Citigroup Inc., JPMorgan Chase & Co., Vanguard Group Inc., and PDT Partners LLC. Company insiders that have sold Vericel company stock in the last year include Jonathan Mark Hopper, Michael Halpin, Sean C Flynn, and Steven C Gilman.
View insider buying and selling activity for Vericel or view top insider-selling stocks.

Which major investors are buying Vericel stock?

VCEL stock was acquired by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, GW&K Investment Management LLC, Fort Washington Investment Advisors Inc. OH, Lisanti Capital Growth LLC, State Street Corp, Royal Bank of Canada, Comerica Bank, and New York State Common Retirement Fund.
View insider buying and selling activity for Vericel or or view top insider-buying stocks.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $26.84.

How much money does Vericel make?

Vericel has a market capitalization of $1.26 billion and generates $156.18 million in revenue each year. The biotechnology company earns $-7.47 million in net income (profit) each year or ($0.25) on an earnings per share basis.

How many employees does Vericel have?

Vericel employs 281 workers across the globe.

When was Vericel founded?

Vericel was founded in 1989.

What is Vericel's official website?

The official website for Vericel is www.vcel.com.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (800) 556-0311, via email at [email protected], or via fax at 617-588-5554.